肝损伤
药品
肺结核
医学
药理学
重症监护医学
病理
出处
期刊:PubMed
[National Institutes of Health]
日期:2024-11-12
卷期号:47 (11): 1069-1090
被引量:13
标识
DOI:10.3760/cma.j.cn112147-20240614-00338
摘要
Rational drug use during the recovery period: During or after liver function recovery, clinicians should comprehensively assess the patient's liver injury severity, presence of liver injury-related risk factors, and tuberculosis severity. Based on this assessment, anti-tuberculosis drugs should be selected rationally (4, C). These recommendations provide clinical evidence and decision-making guidance for the standardized diagnosis and treatment of ATB-DILI.
科研通智能强力驱动
Strongly Powered by AbleSci AI